Tumour Hsp90 is reported to be both overexpressed and more sensitive for Hsp90 inhibitors, creating a potential therapeutic window for Hsp90 inhibitor treatment (Lianos et al. 2015; Miyata et al. 2013). The gene discussed is HSP90AA1; the disease is neoplasm.